Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, today announced it will be presenting at the following upcoming scientific conferences:
Inhibrx Announces Participation in Upcoming Scientific Conferences streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
You should read the following discussion and analysis of our financial condition
and results of operations together with our audited consolidated financial
statements and notes thereto for the. | March 27, 2023
A No-Objection Letter from Health Canada has been received, enabling the initiation of PNT2004’s Phase 1 therapeutic trial using 68Ga-PNT6555 for imaging and 177Lu-PNT6555 for therapy . | May 16, 2022